Sipp Industries Forges Distribution Agreement with SinuSave®'s CBD Nasal Spray
Sipp Industries, Inc., reaches a distribution agreement with SinuSave® regarding their SinuSave® CBD Nasal Spray products.
A recent press release disclosed that Sipp Industries, Inc., (Sipp Industries) has reached a distribution agreement with SinuSave® (1). This deal is in regard to SinuSave®’s patented cannabidiol (CBD) Nasal Spray products which are offered in two dosages, 500mg and 1000mg and is “bacteriostatic” and “bactericidal” (1). Additionally, the CBD nasal spray is formulated with a patented mixture of nine essential oils.
The cannabinoid, CBD, has become well-known to cannabis users for its pain relieving properties. The press release mentions that this cannabinoid might also be of help in relieving allergy, sinusitis, air pollution, and cold symptoms (1). Pertaining to daily nasal hygiene, the CBD nasal spray, is currently the only patented drug-free product created for this purpose.
“This partnership with SinuSave® represents an exciting leap forward for SIPP Industries,” Jakob Jorgensen, CEO of SIPP Industries, mentioned (1). “We are incredibly proud to align ourselves with a product that has the potential to transform the well-being of individuals seeking advanced, effective solutions for nasal health. The patent-pending, nano-emulsified CBD technology showcased in SinuSave's nasal spray is a game-changer, and we are thrilled to be at the forefront of its distribution.”
The Original SinuSave® nasal spray has been around since 2017 (1). Their new CBD product provides similar benefits with the addition of the medical properties the cannabinoid provides.
“The SinuSave® CBD Nasal Spray is set to revolutionize how individuals approach nasal health. With our distribution agreement with SIPP Industries, we are excited to reach more consumers and make a positive impact on their well-being,” Lou Lobel, President of SinuSave®, explained (1). “This strategic partnership is poised to empower consumers seeking alternative, natural solutions for nasal care. It showcases a shared commitment to innovation, quality, and excellence in the wellness landscape.”
According to Sipp Industries press release (1), the global nasal market was previously valued at $24.5 billion in 2022. Data from Verified Market Research foresees these numbers to increase at a compound annual growth rate (CAGR) of 6.7% (1).
Per the distribution agreement, Sipp Industries will be in charge of the distribution, sales,and marketing of SinuSave®’s CBD nasal spray products (1). The items from SinuSave®’s product lineup will be offered in retail stores and online soon. Sipp Industries is also investigating distributing SinuSave®’s products internationally as well.
Reference
- Sipp Industries, Inc. Sipp Industries Announces Distribution Agreement for Patented SinuSave® CBD Nasal Spray https://www.globenewswire.com/news-release/2024/01/23/2814273/0/en/Sipp-Industries-Announces-Distribution-Agreement-for-Patented-SinuSave-CBD-Nasal-Spray.html (accessed Jan 23, 2024).
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
